{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:57:16Z","timestamp":1773849436838,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T00:00:00Z","timestamp":1329868800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s00702-012-0772-4","type":"journal-article","created":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T13:12:29Z","timestamp":1329829949000},"page":"843-850","source":"Crossref","is-referenced-by-count":53,"title":["Longitudinal plasma amyloid beta as a biomarker of Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"119","author":[{"given":"Robert A.","family":"Rissman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Q.","family":"Trojanowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie M.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul S.","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,22]]},"reference":[{"key":"772_CR1","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0196-9781(02)00056-6","volume":"23","author":"N Andreasen","year":"2002","unstructured":"Andreasen N, Blennow K (2002) Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer\u2019s disease. Peptides 23:1205\u20131214","journal-title":"Peptides"},{"key":"772_CR2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/ana.410300509","volume":"30","author":"H Arai","year":"1991","unstructured":"Arai H, Lee VM, Messinger ML, Greenberg BD, Lowery DE, Trojanowski JQ (1991) Expression patterns of beta-amyloid precursor protein (beta-APP) in neural and nonneural human tissues from Alzheimer\u2019s disease and control subjects. Ann Neurol 30:686\u2013693","journal-title":"Ann Neurol"},{"key":"772_CR3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00002093-200207000-00009","volume":"16","author":"Z Arvanitakis","year":"2002","unstructured":"Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR (2002) Serum creatinine levels correlate with plasma amyloid beta protein. Alzheimer Dis Assoc Disord 16:187\u2013190","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"772_CR4","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/01.wnl.0000256043.50901.e3","volume":"68","author":"RJ Bateman","year":"2007","unstructured":"Bateman RJ, Wen G, Morris JC, Holtzman DM (2007) Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 68:666\u2013669","journal-title":"Neurology"},{"key":"772_CR5","doi-asserted-by":"crossref","first-page":"32916","DOI":"10.1074\/jbc.271.51.32916","volume":"271","author":"AL Biere","year":"1996","unstructured":"Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ (1996) Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 271:32916\u201332922","journal-title":"J Biol Chem"},{"key":"772_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2006.09.002","volume":"29","author":"I Blasko","year":"2008","unstructured":"Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragl KH, Fischer P (2008) Conversion from cognitive health to mild cognitive impairment and Alzheimer\u2019s disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging 29:1\u201311","journal-title":"Neurobiol Aging"},{"key":"772_CR7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1172\/JCI19420","volume":"112","author":"JR Cirrito","year":"2003","unstructured":"Cirrito JR, Holtzman DM (2003) Amyloid beta and Alzheimer disease therapeutics: the devil may be in the details. J Clin Invest 112:321\u2013323","journal-title":"J Clin Invest"},{"key":"772_CR8","doi-asserted-by":"crossref","unstructured":"Coppus AM, Schuur M, Vergeer J, Janssens AC, Oostra BA, Verbeek MM, van Duijn CM (2011) Plasma \u03b2 amyloid and the risk of Alzheimer\u2019s disease in Down syndrome. Neurobiol Aging [Epub ahead of print]","DOI":"10.1016\/j.neurobiolaging.2011.08.007"},{"key":"772_CR9","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nm890","volume":"9","author":"R Deane","year":"2003","unstructured":"Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-beta peptide transport across the blood\u2013brain barrier and accumulation in brain. Nat Med 9:907\u2013913","journal-title":"Nat Med"},{"key":"772_CR10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neuron.2004.07.017","volume":"43","author":"R Deane","year":"2004","unstructured":"Deane R, Wu ZH, Sagare A, Davis J, Yan SD, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song XM, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004a) LRP\/amyloid beta-peptide interaction mediates differential brain efflux of A beta isoforms. Neuron 43:333\u2013344","journal-title":"Neuron"},{"key":"772_CR11","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1161\/01.STR.0000143452.85382.d1","volume":"35","author":"R Deane","year":"2004","unstructured":"Deane R, Wu ZH, Zlokovic BV (2004b) RAGE (Yin) versus LRP (Yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood\u2013brain barrier. Stroke 35:2628\u20132631","journal-title":"Stroke"},{"key":"772_CR12","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1126\/science.1067568","volume":"295","author":"RB DeMattos","year":"2002","unstructured":"DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM (2002) Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer\u2019s disease. Science 295:2264\u20132267","journal-title":"Science"},{"key":"772_CR13","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1126\/science.290.5500.2303","volume":"290","author":"N Ertekin-Taner","year":"2000","unstructured":"Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, Ronald J, Blangero J, Hutton M, Younkin SG (2000) Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer\u2019s disease pedigrees. Science 290:2303\u20132304","journal-title":"Science"},{"key":"772_CR14","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1212\/01.wnl.0000278386.00035.21","volume":"70","author":"N Ertekin-Taner","year":"2008","unstructured":"Ertekin-Taner N, Younkin LH, Yager DM, Parfitt F, Baker MC, Asthana S, Hutton ML, Younkin SG, Graff-Radford NR (2008) Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology 70:596\u2013606","journal-title":"Neurology"},{"key":"772_CR15","doi-asserted-by":"crossref","unstructured":"Figurski MJ, Waligorska T, Toledo J, Vanderstichele H, Korecka M, Lee VM-Y, Trojanowski JQ, Shaw LM (2012) Improved protocol for measurement of plasma amyloid-\u03b2 in longitudinal evaluation of ADNI patients. Alzheimer\u2019s Dementia (in press)","DOI":"10.1016\/j.jalz.2012.01.001"},{"key":"772_CR16","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/archneur.60.7.958","volume":"60","author":"H Fukumoto","year":"2003","unstructured":"Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC (2003) Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 60:958\u2013964","journal-title":"Arch Neurol"},{"key":"772_CR17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neulet.2007.09.023","volume":"427","author":"V Giedraitis","year":"2007","unstructured":"Giedraitis V, Sundelof J, Irizarry MC, Garevik N, Hyman BT, Wahlund LO, Ingelsson M, Lannfelt L (2007) The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer\u2019s disease. Neurosci Lett 427:127\u2013131","journal-title":"Neurosci Lett"},{"key":"772_CR18","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1152\/japplphysiol.00966.2005","volume":"100","author":"H Girouard","year":"2006","unstructured":"Girouard H, Iadecola C (2006) Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol 100:328\u2013335","journal-title":"J Appl Physiol"},{"key":"772_CR19","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/archneur.64.3.354","volume":"64","author":"NR Graff-Radford","year":"2007","unstructured":"Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG (2007) Association of low plasma Abeta42\/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64:354\u2013362","journal-title":"Arch Neurol"},{"key":"772_CR20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1212\/01.wnl.0000191403.95453.6a","volume":"66","author":"ME Gurol","year":"2006","unstructured":"Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM (2006) Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66:23\u201329","journal-title":"Neurology"},{"issue":"4","key":"772_CR21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.pneurobio.2010.11.005","volume":"95","author":"H Hampel","year":"2011","unstructured":"Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B (2011) Biomarkers for Alzheimer\u2019s disease therapeutic trials. Prog Neurobiol 95(4):579\u2013593","journal-title":"Prog Neurobiol"},{"issue":"2","key":"772_CR100","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JAD-2009-0966","volume":"16","author":"SF Hansson","year":"2009","unstructured":"Hansson SF, Andr\u00e9asson U, Wall M, Skoog I, Andreasen N, Wallin A, Zetterberg H, Blennow K (2009) Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer\u2019s disease patients. J Alzheimers Dis 16(2):389\u2013397","journal-title":"J Alzheimers Dis"},{"key":"772_CR23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3233\/JAD-2010-101335","volume":"23","author":"E Head","year":"2011","unstructured":"Head E, Doran E, Nistor M, Hill M, Schmitt FA, Haier RJ, Lott IT (2011) Plasma amyloid-beta as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis 23:399\u2013409","journal-title":"J Alzheimers Dis"},{"key":"772_CR24","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO;2-9","volume":"45","author":"M Jensen","year":"1999","unstructured":"Jensen M, Schroder J, Blomberg M, Engvall B, Pantel J, Ida N, Basun H, Wahlund LO, Werle E, Jauss M, Beyreuther K, Lannfelt L, Hartmann T (1999) Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer\u2019s disease and declines with disease progression. Ann Neurol 45:504\u2013511","journal-title":"Ann Neurol"},{"key":"772_CR25","doi-asserted-by":"crossref","first-page":"10673","DOI":"10.1073\/pnas.0700148104","volume":"104","author":"JE Kang","year":"2007","unstructured":"Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM (2007) Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci USA 104:10673\u201310678","journal-title":"Proc Natl Acad Sci USA"},{"key":"772_CR26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1523\/JNEUROSCI.21-02-00372.2001","volume":"21","author":"T Kawarabayashi","year":"2001","unstructured":"Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer\u2019s disease. J Neurosci 21:372\u2013381","journal-title":"J Neurosci"},{"key":"772_CR27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0009-8981(97)00207-6","volume":"270","author":"AR Koudinov","year":"1998","unstructured":"Koudinov AR, Berezov TT, Kumar A, Koudinova NV (1998) Alzheimer\u2019s amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin Chim Acta 270:75\u201384","journal-title":"Clin Chim Acta"},{"key":"772_CR28","doi-asserted-by":"crossref","first-page":"11693","DOI":"10.1523\/JNEUROSCI.2766-05.2005","volume":"25","author":"FM Laird","year":"2005","unstructured":"Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25:11693\u201311709","journal-title":"J Neurosci"},{"key":"772_CR29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.brainresbull.2004.11.024","volume":"65","author":"GD Lee","year":"2005","unstructured":"Lee GD, Aruna JH, Barrett PM, Lei DL, Ingram DK, Mouton PR (2005) Stereological analysis of microvascular parameters in a double transgenic model of Alzheimer\u2019s disease. Brain Res Bull 65:317\u2013322","journal-title":"Brain Res Bull"},{"key":"772_CR30","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1212\/01.wnl.0000306696.82017.66","volume":"70","author":"OL Lopez","year":"2008","unstructured":"Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, Chang YF, Tracy R, DeKosky ST (2008) Plasma amyloid levels and the risk of AD in normal subjects in the cardiovascular health study. Neurology 70:1664\u20131671","journal-title":"Neurology"},{"key":"772_CR31","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/1531-8249(199904)45:4<537::AID-ANA20>3.0.CO;2-2","volume":"45","author":"E Matsubara","year":"1999","unstructured":"Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, Shoji M (1999) Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer\u2019s disease and Down\u2019s syndrome. Ann Neurol 45:537\u2013541","journal-title":"Ann Neurol"},{"key":"772_CR32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1523\/JNEUROSCI.23-01-00029.2003","volume":"23","author":"Y Matsuoka","year":"2003","unstructured":"Matsuoka Y, Saito M, LaFrancois J, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K (2003) Novel therapeutic approach for the treatment of Alzheimer\u2019s disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 23:29\u201333","journal-title":"J Neurosci"},{"key":"772_CR33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/WAD.0b013e3181aba61e","volume":"23","author":"Y Matsuoka","year":"2009","unstructured":"Matsuoka Y, Andrews HF, Becker AG, Gray AJ, Mehta PD, Sano MC, Dalton AJ, Aisen PS (2009) The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome. Alzheimer Dis Assoc Disord 23:315\u2013318","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"386\u2013395","key":"772_CR34","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1016\/j.jalz.2011.05.2243","volume":"7","author":"N Mattsson","year":"2011","unstructured":"Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Llado A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O\u2019Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schroder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K (2011) The Alzheimer\u2019s association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7(386\u2013395):e386","journal-title":"Alzheimers Dement"},{"issue":"3","key":"772_CR104","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/1531-8249(199909)46:3<412::AID-ANA19>3.0.CO;2-A","volume":"46","author":"R Mayeux","year":"1999","unstructured":"Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, Mehta PD (1999) Plasma amyloid beta-peptide 1-42 and incipient Alzheimer\u2019s disease. Ann Neurol 46(3):412\u2013416","journal-title":"Ann Neurol"},{"key":"772_CR35","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","volume":"61","author":"R Mayeux","year":"2003","unstructured":"Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD (2003) Plasma A[beta]40 and A[beta]42 and Alzheimer\u2019s disease: relation to age, mortality, and risk. Neurology 61:1185\u20131190","journal-title":"Neurology"},{"key":"772_CR36","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/archneurol.2009.207","volume":"66","author":"OI Okereke","year":"2009","unstructured":"Okereke OI, Xia W, Selkoe DJ, Grodstein F (2009) Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol 66:1247\u20131253","journal-title":"Arch Neurol"},{"issue":"7","key":"772_CR101","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3109\/13547500903108423","volume":"14","author":"AE Roher","year":"2009","unstructured":"Roher AE, Maarouf CL, Sue LI, Hu Y, Wilson J, Beach TG (2009) Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer\u2019s disease. Biomarkers 14(7):493\u2013501","journal-title":"Biomarkers"},{"key":"772_CR37","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat Med 2:864\u2013870","journal-title":"Nat Med"},{"key":"772_CR38","doi-asserted-by":"crossref","first-page":"14052","DOI":"10.1073\/pnas.0805902105","volume":"105","author":"N Schupf","year":"2008","unstructured":"Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R (2008) Peripheral Abeta subspecies as risk biomarkers of Alzheimer\u2019s disease. Proc Natl Acad Sci USA 105:14052\u201314057","journal-title":"Proc Natl Acad Sci USA"},{"key":"772_CR39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev.ne.17.030194.002421","volume":"17","author":"DJ Selkoe","year":"1994","unstructured":"Selkoe DJ (1994) Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 17:489\u2013517","journal-title":"Annu Rev Neurosci"},{"key":"772_CR40","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0b013e3182166df5","volume":"76","author":"CA Shaw","year":"2011","unstructured":"Shaw CA, Li Y, Wiszniewska J, Chasse S, Zaidi SN, Jin W, Dawson B, Wilhelmsen K, Lupski JR, Belmont JW, Doody RS, Szigeti K (2011) Olfactory copy number association with age at onset of Alzheimer disease. Neurology 76:1302\u20131309","journal-title":"Neurology"},{"key":"772_CR41","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1172\/JCI10498","volume":"106","author":"M Shibata","year":"2000","unstructured":"Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer\u2019s amyloid-ss(1\u201340) peptide from brain by LDL receptor-related protein-1 at the blood\u2013brain barrier. J Clin Invest 106:1489\u20131499","journal-title":"J Clin Invest"},{"key":"772_CR42","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/990114","volume":"402","author":"S Sinha","year":"1999","unstructured":"Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402:537\u2013540","journal-title":"Nature"},{"issue":"2","key":"772_CR102","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/archneurol.2007.57","volume":"65","author":"J Sundel\u00f6f","year":"2008","unstructured":"Sundel\u00f6f J, Giedraitis V, Irizarry MC, Sundstr\u00f6m J, Ingelsson E, R\u00f6nnemaa E, Arnl\u00f6v J, Gunnarsson MD, Hyman BT, Basun H, Ingelsson M, Lannfelt L, Kilander L (2008) Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol 65(2):256\u2013263","journal-title":"Arch Neurol"},{"key":"772_CR43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bbrc.2009.05.037","volume":"385","author":"S Takeda","year":"2009","unstructured":"Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R (2009) Elevation of plasma beta-amyloid level by glucose loading in Alzheimer mouse models. Biochem Biophys Res Commun 385:193\u2013197","journal-title":"Biochem Biophys Res Commun"},{"key":"772_CR44","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s11095-006-0208-7","volume":"23","author":"C Tamaki","year":"2006","unstructured":"Tamaki C, Ohtsuki S, Iwatsubo T, Hashimoto T, Yamada K, Yabuki C, Terasaki T (2006) Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm Res 23:1407\u20131416","journal-title":"Pharm Res"},{"key":"772_CR45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ana.410410220","volume":"41","author":"T Tokuda","year":"1997","unstructured":"Tokuda T, Fukushima T, Ikeda S, Sekijima Y, Shoji S, Yanagisawa N, Tamaoka A (1997) Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down\u2019s syndrome. Ann Neurol 41:271\u2013273","journal-title":"Ann Neurol"},{"key":"772_CR46","doi-asserted-by":"crossref","unstructured":"Toledo JB, Toledo E, Jack CR, Jagust W, Lee VM-Y, Shaw LM, Trojanowski JQ Initiative f.t.A.s.D.N (2011a) Cardiovascular risk factors, cortisol, and amyloid-beta deposition in Alzheimer\u2019s disease neuroimaging initiative. Alzheimer\u2019s Dementia (in press)","DOI":"10.1016\/j.jalz.2011.08.008"},{"key":"772_CR47","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00401-011-0861-8","volume":"122","author":"JB Toledo","year":"2011","unstructured":"Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR Jr, Jagust W, Decarli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM (2011b) Factors affecting A\u03b2 plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 122(4):401\u2013413","journal-title":"Acta Neuropathol"},{"key":"772_CR48","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/ajcn\/82.3.627","volume":"82","author":"KL Tucker","year":"2005","unstructured":"Tucker KL, Qiao N, Scott T, Rosenberg I, Spiro A 3rd (2005) High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. Am J Clin Nutr 82:627\u2013635","journal-title":"Am J Clin Nutr"},{"issue":"8","key":"772_CR103","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1474-4422(06)70501-4","volume":"5","author":"M Van Oijen","year":"2006","unstructured":"Van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM (2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5(8):655\u2013660","journal-title":"Lancet Neurol"},{"key":"772_CR49","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.286.5440.735","volume":"286","author":"R Vassar","year":"1999","unstructured":"Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) Beta-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735\u2013741","journal-title":"Science"},{"key":"772_CR50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jama.2010.1995","volume":"305","author":"K Yaffe","year":"2011","unstructured":"Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, Younkin LH, Kuller L, Ayonayon HN, Ding J, Harris TB (2011) Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305:261\u2013266","journal-title":"JAMA"},{"key":"772_CR51","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0928-4257(98)80035-1","volume":"92","author":"SG Younkin","year":"1998","unstructured":"Younkin SG (1998) The role of A beta 42 in Alzheimer\u2019s disease. J Physiol Paris 92:289\u2013292","journal-title":"J Physiol Paris"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-012-0772-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-012-0772-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-012-0772-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T01:51:01Z","timestamp":1561341061000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-012-0772-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,22]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["772"],"URL":"https:\/\/doi.org\/10.1007\/s00702-012-0772-4","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,22]]}}}